These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 32954807)

  • 41. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
    Bartlett NL; Smith MR; Siddiqi T; Advani RH; O'Connor OA; Sharman JP; Feldman T; Savage KJ; Shustov AR; Diefenbach CS; Oki Y; Palanca-Wessels MC; Uttarwar M; Li M; Yang J; Jacobsen ED
    Leuk Lymphoma; 2017 Jul; 58(7):1607-1616. PubMed ID: 27868471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
    Gouni S; Rosenthal AC; Crombie JL; Ip A; Kamdar MK; Hess B; Feng L; Watson G; Ayers A; Neelapu SS; Khurana A; Lin Y; Iqbal M; Merryman RW; Strati P
    Blood Adv; 2022 May; 6(9):2757-2762. PubMed ID: 35240681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.
    Sawalha Y; Maddocks K
    Onco Targets Ther; 2020; 13():5123-5133. PubMed ID: 32606733
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
    Patel KK; Isufi I; Kothari S; Foss F; Huntington S
    Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Lu T; Gibiansky L; Li X; Li C; Shi R; Agarwal P; Hirata J; Miles D; Chanu P; Girish S; Jin JY; Lu D
    Leuk Lymphoma; 2020 Dec; 61(12):2905-2914. PubMed ID: 32705923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
    Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
    Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma.
    Abdur Raqib M; Haseeb A; Shafique MA; Fadlalla Ahmed TK; Mustafa MS
    Pediatric Health Med Ther; 2023; 14():323-331. PubMed ID: 37867604
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma.
    Takakuwa T; Okayama Y; Nakamae H; Kuno M; Makuuchi Y; Harada N; Okamura H; Nishimoto M; Nakashima Y; Koh H; Hino M
    Ann Hematol; 2022 Jul; 101(7):1609-1610. PubMed ID: 35218398
    [No Abstract]   [Full Text] [Related]  

  • 50. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
    Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
    Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
    Segman Y; Ribakovsky E; Avigdor A; Goldhecht Y; Vainstein V; Goldschmidt N; Harlev S; Horwitz N; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Zektser M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Herishanu Y; Ram R; Perry C; Avivi I
    Leuk Lymphoma; 2021 Jan; 62(1):118-124. PubMed ID: 32981410
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment strategies for patients with diffuse large B-cell lymphoma.
    Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
    Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
    Deng R; Gibiansky L; Lu T; Flowers CR; Sehn LH; Liu Q; Agarwal P; Liao MZ; Dere R; Lee C; Man G; Hirata J; Li C; Miles D
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):1055-1066. PubMed ID: 38622879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
    Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
    Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
    [No Abstract]   [Full Text] [Related]  

  • 55. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
    Flowers CR; Matasar MJ; Herrera AF; Hertzberg M; Assouline S; Demeter J; McMillan A; Mehta A; Opat S; Trnňný M; Musick L; Hirata J; Yang A; Sehn LH
    Haematologica; 2024 Apr; 109(4):1194-1205. PubMed ID: 37767550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type.
    Oka S; Ono K; Nohgawa M
    Ann Hematol; 2022 Oct; 101(10):2353-2354. PubMed ID: 35943589
    [No Abstract]   [Full Text] [Related]  

  • 57. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
    Dal MS; Ulu BU; Uzay A; Akay OM; Beşışık S; Yenerel MN; Çelik S; Kaynar L; Yücel OK; Deveci B; Sönmez M; Mehtap Ö; Beköz HS; Sunu C; Salim O; Ulaş T; Kartı S; Altuntaş F; Ferhanoğlu B; Tuğlular TF
    Ann Hematol; 2023 Jan; 102(1):133-140. PubMed ID: 36401621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
    Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine.
    Lv K; Kong F; Yu M; Zhou Y; Li F
    Ann Hematol; 2024 Mar; 103(3):1017-1019. PubMed ID: 38155243
    [No Abstract]   [Full Text] [Related]  

  • 60. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Harris LJ; Patel K; Martin M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.